Form 4: Haemonetics CEO Simon Adjusts Holdings

Haemonetics Corporation reports changes in beneficial ownership for President & CEO Christopher Simon, including stock transactions and RSU vesting.

Summary

• Christopher Simon, President & CEO of Haemonetics Corp., reported changes in his beneficial ownership of company stock.
• On May 15, 2026, 9,681 shares of common stock were disposed of at a price of $56.29 per share, noted as shares withheld for tax obligations related to RSU vesting.
• Additionally, 78,344 Restricted Stock Units (RSUs) were awarded, which vest in three annual installments.
• Following these transactions, Simon beneficially owns 444,704 shares of common stock.
• The filing also notes the purchase of 497 shares under the Haemonetics Corporation Employee Stock Purchase Plan on April 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and RSU vesting, with no significant positive or negative financial implications immediately apparent.

Positives

• Award of 78,344 RSUs indicates continued incentive alignment for key executive leadership.
• The purchase of 497 shares under the Employee Stock Purchase Plan by the CEO demonstrates personal investment in the company.

Negatives

• 9,681 shares were withheld for tax obligations, representing a disposition of stock.

Future Outlook

The RSUs awarded vest in three annual installments, with specific percentages vesting on the first, second, and third anniversaries of the grant date, indicating a phased release of equity over time.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions, providing transparency into insider activity within the medical technology sector.

Stakeholder Impact

• Shareholders gain insight into executive compensation and stock ownership patterns.
• Employees may note the CEO's participation in the Employee Stock Purchase Plan.

Next Steps

• Continued vesting of RSUs over the next three years.
• Ongoing reporting of any further changes in beneficial ownership by Christopher Simon.

Key Dates

Keywords

Haemonetics Corp, HAE, Form 4, Beneficial Ownership, Christopher Simon, RSU, Stock Vesting, Insider Trading, Executive Compensation